drug
dexamethasone
Marketedupdated 5mo agoby Fera Pharmaceuticals LLC
Approvedcommunity read0 votes
indications
investigational
Multiple SclerosisIBD (Crohn's + UC)Rheumatoid ArthritisPsoriasisLupusAsthma
all catalysts(10)
phase 0 trial completion · 1
phase 2 completion · 7
Apr 25, 2026
phase 2 completion
Nizam's Institute of Medical Sciences — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 25, 2026
phase 2 completion
Assiut University — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 27, 2026
phase 2 completion
BC Children's Hospital Research Institute — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 28, 2026
phase 2 completion
West China Hospital of Stomatology — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 30, 2026
phase 2 completion
Buddhachinaraj Hospital — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 30, 2026
phase 2 completion
Dalian Municipal Central Hospital — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 30, 2026
phase 2 completion
ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini — dexamethasone (Phase II Trial Completion)
dexamethasone
→
phase 2 initiation · 1
Trials studying dexamethasone
- phase2Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
- phase3A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- phase3A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
- phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
- phase2Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- phase2Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
- phase2Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
- phase2EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 3, 2026
2 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Dec 18, 2037formulationUS 10537585
- Dec 18, 2037formulationUS 11304961
FDA exclusivities (1)
- Oct 3, 2026ODE-271Orphan Drug (7y)2d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 58m ago
Found something off?
comments(0)
5-min edit window · permanent after that